全文获取类型
收费全文 | 1906篇 |
免费 | 162篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 33篇 |
妇产科学 | 38篇 |
基础医学 | 384篇 |
口腔科学 | 48篇 |
临床医学 | 211篇 |
内科学 | 364篇 |
皮肤病学 | 32篇 |
神经病学 | 196篇 |
特种医学 | 50篇 |
外科学 | 187篇 |
综合类 | 6篇 |
一般理论 | 2篇 |
预防医学 | 180篇 |
眼科学 | 38篇 |
药学 | 115篇 |
中国医学 | 2篇 |
肿瘤学 | 180篇 |
出版年
2024年 | 4篇 |
2023年 | 20篇 |
2022年 | 29篇 |
2021年 | 45篇 |
2020年 | 40篇 |
2019年 | 62篇 |
2018年 | 45篇 |
2017年 | 51篇 |
2016年 | 66篇 |
2015年 | 72篇 |
2014年 | 84篇 |
2013年 | 117篇 |
2012年 | 193篇 |
2011年 | 152篇 |
2010年 | 94篇 |
2009年 | 110篇 |
2008年 | 137篇 |
2007年 | 119篇 |
2006年 | 97篇 |
2005年 | 103篇 |
2004年 | 100篇 |
2003年 | 98篇 |
2002年 | 89篇 |
2001年 | 13篇 |
2000年 | 6篇 |
1999年 | 15篇 |
1998年 | 13篇 |
1997年 | 6篇 |
1996年 | 12篇 |
1995年 | 12篇 |
1994年 | 6篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1974年 | 3篇 |
1970年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有2076条查询结果,搜索用时 875 毫秒
71.
Agnes Ziobrowska-Bech Anne Winther-Larsen Britta Kremke Tina Parkner Cindy Soendersoe Knudsen 《Scandinavian journal of clinical and laboratory investigation》2019,79(1-2):123-125
The GAD65 and IA-2 antibodies (Abs) are biomarkers of the development of type 1 diabetes mellitus (T1DM) in both children and adults. The upper reference limit for the autoantibodies made by the manufacture was established on an adult Chinese population. Here, we established upper reference limits for Northern European adults and children in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. Serum samples from healthy Danish children (0–18 years) and adults (18–70 years) were analysed for GAD65Ab and IA-2Ab using MAGLUMI 800 Chemiluminescence Immunoassay (CLIA). The Kruskal–Wallis test was used for evaluating differences between gender and age groups. No gender or age differences were found for neither GAD65Ab nor IA-2Ab, and a combined upper reference limit for both children and adults could be established. An upper reference limit of 5.1?IU/mL was defined for GAD65Ab and 11.5?U/mL for IA-2Ab. Our results showed a substantial discrepancy with the reference limits established by the manufacturer. 相似文献
72.
73.
Alcohol consumption and cancer of the gastrointestinal tract 总被引:2,自引:0,他引:2
74.
Ljungberg K Hassan MS Islam MN Siddiqui MA Aziz MM Wahren B Islam KB Leitner T 《AIDS research and human retroviruses》2002,18(9):667-670
We analyzed the genetic diversity of HIV-1 circulating in Bangladesh by direct sequencing and subsequent phylogenetic analysis of the V3 region of the env gene and p17 fragment of the gag gene from nine unrelated patients. The sequences from one sample grouped into subtype A, five samples grouped into subtype C, and one grouped into subtype G. In addition, two patients appeared to be infected with different recombinant viruses consisting of subtype A and unclassifiable viral sequences. Epidemiological analysis revealed heterosexual transmission in the majority of cases. Furthermore, most subjects had a history of traveling, either to India or to the Arabian Peninsula. This study shows that several HIV-1 subtypes are circulating in Bangladesh, and we conclude that there must have been several introductions of HIV-1 into the Bangladeshi population. 相似文献
75.
76.
Carlo Dufour Marta Pillon Jakob Passweg Gerard Socié Andrea Bacigalupo Genny Franceschetto Elisa Carraro Rosi Oneto Antonio Maria Risitano Regis Peffault de Latour André Tichelli Alicia Rovo Christina Peters Britta Hoechsmann Sujith Samarasinghe Austin G Kulasekararaj Hubert Schrezenmeier Mahmoud Aljurf Judith Marsh 《Haematologica》2014,99(10):1574-1581
We analyzed the outcome of 537 adolescents (age 12–18 years) with idiopathic aplastic anemia included in the database of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation comparing: i) matched family donor hematopoietic stem cell transplantation performed as first-line treatment with ii) front-line immunosuppressive therapy not followed by subsequent transplant given for failure and with iii) hematopoietic stem cell transplantation performed after failed front-line immunosuppressive therapy. Overall survival was 86% in the matched family donor hematopoietic stem cell transplantation group, 90% in patients given front-line immunosuppressive alone (those who did not fail this treatment and who did not receive subsequent rescue with hematopoietic stem cell transplantation) and 78% in subjects who underwent hematopoietic stem cell transplantation post failed front-line immunosuppressive therapy (P=0.14). Event-free survival in the same groups was respectively 83%, 64% and 71% (P=0.04). Cumulative incidence of rejection was 8% in matched family donor hematopoietic stem cell transplantation and 9% in transplants post failed front-line immunosuppression (P=0.62). Cumulative incidence of acute graft-versus-host disease was 12% in matched family donor transplants and 18% in transplants post failed immunosuppression (P=0.18). Chronic graft-versus-host disease was higher in matched family donor hematopoietic stem cell transplantation (8%) than in transplants post failed immunosuppressive therapy (20%) (P=0.0009). Cumulative incidence of post-therapy malignancies was 0.7% in matched family donor transplantations, 7% in transplantations post failed immunosuppression and 21% after front-line immunosuppression (P=0.0017). In the whole cohort, under multivariate analysis, the diagnosis to treatment interval of two months or under positively affected overall survival whereas up-front immunosuppression alone (with no subsequent rescue transplants) negatively affected event-free survival. In transplanted patients an interval from diagnosis to treatment of 2 months or under, bone marrow as source of cells and first-line matched family donor transplants provided a significant advantage in overall and event-free survival. Aplastic anemia in adolescents has a very good outcome. If a matched family donor is available, hematopoietic stem cell transplantation using bone marrow cells is the first choice treatment. If such a donor is not available, immunosuppressive treatment may still be an acceptable second choice, also because, in case of failure, hematopoietic stem cell transplantation is a very good rescue option. 相似文献
77.
78.
Funding of diagnostic and therapeutic methods in Germany's statutory health insurance (SHI) follows a dichotomy: in outpatient care, only methods with proven benefit are reimbursed while in inpatient care, all methods may be provided unless they are excluded due to proven harm or lack of benefit. In January 2012, a new section 137e was added to the Social Code Book V (SGB V), allowing for the inclusion of innovative and potentially beneficial diagnostic or therapeutic methods in the SHI benefit basket, while additional evidence regarding their effectiveness and safety must be gathered. In 2013, the Federal Joint Committee (G-BA) has specified the details of this new approach, which can be considered a variety of “Coverage with Evidence Development” (CED). Our comparison with CED schemes in selected countries reveals a dependence of the CED implementation on the encompassing healthcare system. However, we identify a clear legislative foundation, a definitive decision-making body, the possibility to obtain public funding, and the preference for high quality study designs as constituting factors of an emerging international standard for CED. In addition, it is necessary to ensure the suitability of circumstances and technologies for the successful application of CED in a clear and transparent way. 相似文献
79.
80.